Tricyclic benzazepine vasopressin antagonists

The present invention provides the compounds of general formula (I) and their pharmaceutically acceptable salts, their therapeutic compositions containing them, and the production process for the preparation. In one of the highly valuable compounds of formula (I), the atricyllic oxidizing unit is a residue of compound 3b and the resulting residue is the acyl residue of compound (20a) (chemical synthesis of these compounds also from these scavengers). In formula (3b), the ring containing Z z is preferably a benzene, pyridine or thiophene ring; Preferably, Y is - (CH2) n-, wherein n is 0, 1 or 2; and m is 0, 1 or 2. The cyclic moiety of formula (f) is a 5- to 6-membered heterocycle containing a 5- or 6-membered ring, usually a nitric oxide moiety; R1 and R2 are hydrogen, halo, alkyl, alkyloxy; R6 is a substituted aminoalkyl. The compounds of the present invention have a functional affinity for the vasopressin V1 or V2 receptor. The compounds have antihypertensive effects, they can be used to treat diseases characterized by excessive water reabsorption of avese, and lossy heart failure, hepatic cirrhosis, nephrotic syndrome, neuropathic disorder, pulmonary disease and hyponatraemia. ŕ